

Attorney Docket No.: 320727.00201

Sustomer No. 27160

U.S. Patent Application No. 10/620,433

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

John W. LUDLOW et al. : Group Art Unit: 1632

Application No.: 10/620,433 : Examiner: Not Yet Assigned

Filed: July 17, 2003 : Confirmation No.: Not Yet Assigned

For: METHOD FOR OBTAINING VIABLE:

HUMAN CELLS, INCLUDING

HEPATIC STEM/PROGENITOR CELLS

November 2, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Atty. Dkt. No.: 320727.00201

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. §1.56 and in accordance with the practice under 37 C.F.R. §§1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Forms PTO/SB/08A and PTO/SB/08B. In accordance with current practice, copies of any listed U.S. Patent Documents are not being provided.

FORMAL MATTERS

In accordance with 37 C.F.R. § 1.97(b)(3), since a first Official Action on the merits of the subject application has not yet been issued, neither a certificate, petition nor payment of a fee is believed to be required for this Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any fee which may be required in connection with this paper to Deposit Account No. 50-1710.

Attorney Docket No.: 320727.00201 U.S. Patent Application No. Customer No. 27160 10/620,433

CONCLUSION

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Forms PTO/SB/08A and PTO/SB/08B be returned indicating that such information has been considered.

Applicant's undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 625-3500. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

Gilberto M. Villacorta, Ph.D. Registration No. 34,038 Sunit Talapatra, Ph.D. Registration No. 54,482

Patent Administrator KATTEN MUCHIN ZAVIS ROSENMAN 525 West Monroe Street, Suite 1600 Chicago, Illinois 60661-3963 (202) 625-3500

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

320727.00201

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB Complete if Known Substitute for form 1449/PTO **Application Number** 10/620,433 NOV 0 Z 2004 Filing Date July 17, 2003 INFORMATION DISCLOSURE John W. LUDLOW First Named Inventor STATEMENT BY APPLICANT Art Unit 1632 (Use as many sheets as necessary) PADEMA **Examiner Name** Not Yet Assigned

Sheet

Attorney Docket Number

Examiner	Cite	Document Number	Publication Date	DOCUMENTS Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	1	^{US-} 4,683,195	07/28/1987	MULLIS et al.	
	2	^{US-} 5,559,022	09/24/1996	NAUGHTON et al.	
	3	^{US-} 4,298,002	11/03/1981	RONEL et al.	
	4	^{US-} 5,308,701	05/03/1994	COHEN et al.	
		US-			
		US-			
		US-		100	
		US-			
		US-	-		
		US-			
-		US-			
		US-			

		FOREIGN	PATENT DOCL	IMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ "Number * "Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	5	WO 00/75275 A2	12/14/00	University of North Carolina		75

Examiner	Date	
Signature		
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute	e for form 1449/PTO				Complete if Known
Odosuluk	0 10/10/11/ 1 44 3// 10	•		Application Number	10/620,433
INFO	PRMATIOI	N DIS	CLOSURE	Filing Date	July 17, 2003
STA	TEMENT	BY A	PPLICANT	First Named Inventor	John W. LUDLOW
	(Use as many si	haafe as n	ocossand	Art Unit	1632
	(Use as many si	ieets as in	ecessary)	Examiner Name	Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number	320727.00201

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	6	Kubota H and Reid LM. 2000, "Clonogenic hepatoblasts, common precursors for hepatocytic and biliary lineages, are lacking classical major histocompatibility complex class I antigen", Proceedings of the National Academy of Sciences (USA) 97: 12132-12137.	~
	7	Strom SC, Chowdhury JR, and Fox IJ. 1999, "Hepatocyte transplantation for the treatment of human disease (Review)", Seminars in Liver Disease 19: 39-48.	•
	8	Fox et al., I. J., 1998, "Treatment of the Crigler-Najjar Syndrome Type I with hepatocyte transplantation," New England Journal of Medicine, 338:1422-1426.	~
	9	Gupta et al., 1992, "Hepatocyte Transplantation: Development of New Systems for Liver Repopulation and Gene Therapy", Seminars in Liver Disease 12, 321.	V
	10	Wilson et al., 1990, "Temporary Amelioration of Hyperlipidemia in Low Density Lipoprotein Receptor-Deficient Rabbits Transplanted with Genetically Modified Hepatocytes", Proceedings of the National Academy of Sciences USA 87:8437.	~
	11	Wu et al., 1991, "Receptor-Mediated Gene Delivery In Vivo", Journal of Biological Chemistry 266:14338.	~
	12	Logan & Shenk, 1984, "Adenovirus Tripartite Leader Sequence Enhances Translation of mRNAs Late After Infection", Proc. Natl. Acad. Sci. USA 81:3655-3659.	~
	13	Mackett et al., 1982, "Vaccinia Virus: A Selectable Eukaryotic Cloning and Expression Vector", Proc. Natl. Acad. Sci. USA 79:7415-7419.	~
	14	Mackett et al., 1984, "General Method for Production and Selection of Infectious Vaccinia Virus Recombinants Expressing Foreign Genes", J. Virol. 49:857-864.	~
	15	Panicali et al., 1982, "Construction of Poxviruses as Cloning Vectors: Insertion of the Thymidine Kinase Gene from Herpes Simplex Virus into the DNA of Infectious Vaccinia Virus", Proc. Natl. Acad. Sci. USA 79:4927-4931.	~

Examiner	Date	
Signature	I Consi	dered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions deducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do Not SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449/PTO			Complete if Known			
Cubosion				Application Number	10/620,433		
INFO	ORMATION	I DIS	CLOSURE	Filing Date	July 17, 2003		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	John W. LUDLOW		
	(Use as many she	acte ac n	ococcand	Art Unit	1632		
(ose as many sneets as necessary)				Examiner Name	Not Yet Assigned		
Sheet	3	of	4	Attorney Docket Number	320727.00201		

	* * * * * * * * * * * * * * * * * * * *	
	NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
16	Sarver, et al., 1981, "Bovine Papilloma Virus Deoxyribonucleic Acid: a Novel Eucaryotic Cloning Vector", Mol. Cell. Biol. 1:486.	~
17	Cone & Mulligan, 1984, "High-Efficiency Gene Transfer into Mammalian Cells: Generation of Helper-Free Recombinant Retrovirus with Broad Mammalian Host Range", Proc. Natl. Acad. Sci. USA 81:6349-6353.	~
18	Wigler, et al., 1977, "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell 11:223.	~
19	Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026.	~
20	Lowy, et al., 1980, "Isolation of Transforming DNA: Cloning the Hamster aprt Gene", Cell 22:817.	~
21	Wigler, et al., 1980, "Transformation of Mammalian Cells with an Amplifiable Dominant-Acting Gene", Proc. Natl. Acad. Sci. USA 77:3567.	~
22	O'Hare, et al., 1981, "Transformation of Mouse Fibroblasts to Methotrexate Resistance by a Recombinant Plasmid Expressing a Prokaryotic Dihydrofolate Reductase", Proc. Natl. Acad. Sci. USA 78:1527.	V
23	Mulligan & Berg, 1981, "Selection for Animal Cells that Express the Escherichia coli Gene Coding for Xanthine-guanine Phosphoribosyltransferase", Proc. Natl. Acad. Sci. USA 78:2072.	V
24	Colberre-Garapin, et al., 1981, "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol. 150:1.	~
25	Santerre, et al., 1984, "Expression of Prokaryotic Genes for Hygromycin B and G418 Resistance as Dominant-Selection Markers in Mouse L Cells", Gene 30:147.	~
	16 17 18 19 20 21 22 23	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published. Sarver, et al., 1981, "Bovine Papilloma Virus Deoxyribonucleic Acid: a Novel Eucaryotic Cloning Vector", Mol. Cell. Biol. 1:486. Cone & Mulligan, 1984, "High-Efficiency Gene Transfer into Mammalian Cells: Generation of Helper-Free Recombinant Retrovirus with Broad Mammalian Host Range", Proc. Natl. Acad. Sci. USA 81:6349-6353. Wigler, et al., 1977, "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell 11:223. Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026. Lowy, et al., 1980, "Isolation of Transforming DNA: Cloning the Hamster aprt Gene", Cell 22:817. Wigler, et al., 1980, "Transformation of Mammalian Cells with an Amplifiable Dominant-Acting Gene", Proc. Natl. Acad. Sci. USA 77:3567. O'Hare, et al., 1981, "Transformation of Mouse Fibroblasts to Methotrexate Resistance by a Recombinant Plasmid Expressing a Prokaryotic Dihydrofolate Reductase", Proc. Natl. Acad. Sci. USA 78:1527. Mulligan & Berg, 1981, "Selection for Animal Cells that Express the Escherichia coli Gene Coding for Xanthine-guanine Phosphoribosyltransferase", Proc. Natl. Acad. Sci. USA 78:2072. Colberre-Garapin, et al., 1981, "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol. 150:1.

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a valid OMB contains.

Substitut	e for form 1449/PTO		==-		Complete if Known	\
Cabbandi	3 10/ 10/11/14/0// 10			Application Number	10/620,433	
INFO	DRMATION	I DIS	CLOSURE	Filing Date	July 17, 2003	_
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	John W. LUDLOW	
	(Use as many she	note an n	ooossand	Art Unit	1632	
	(USU as many sne	7013 dS 11	ecessary)	Examiner Name	Not Yet Assigned	_
Sheet	4	of	4	Attorney Docket Number	320727.00201	

Cito	NON PATENT LITERATURE DOCUMENTS	
No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
26	Hartman & Mulligan, 1988, "Two Dominant-acting Selectable Markers for Gene Transfer Studies in Mammalian Cells", Proc. Natl. Acad. Sci. USA 85:8047.	/
27	Naldini et al., 1996, "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector", Science 272:263-267.	,
28	Brister et al., 2002, "Hepatitis C Virus Non-Structural Protein 3-Specific Cellular Immune Responses Following Single or Combined Immunization with DNA or Recombinant Semliki Forest Virus Particles", J. Gen. Virol. 83 (Pt. 2):369-381.	~
		7
	26 27	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Hartman & Mulligan, 1988, "Two Dominant-acting Selectable Markers for Gene Transfer Studies in Mammalian Cells", Proc. Natl. Acad. Sci. USA 85:8047. Naldini et al., 1996, "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector", Science 272:263-267. Brister et al., 2002, "Hepatitis C Virus Non-Structural Protein 3-Specific Cellular Immune Responses Following Single or Combined Immunization with DNA or Recombinant Semliki Forest Virus Particles",

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.